Nicholas G. Avgeropoulos, M.D.

Professional Positions/ Academic Appointment/Board Certification / Post-Graduate Training/ Education/ Clinical Research Experience/ Clinical Trials/Laboratory Clinical Research/Abstracts/Manuscripts/Book Chapters/Editorial Responsibilities/Other Publications/Teaching Positions/Hospital Privileges/ Professional Organizations/Additional Administrative Positions/ Licensure

                                                                                                                               TO TOP

                                                                                                                         TO TOP

                                                                                                    TO TOP

Principal Investigator ‘Phase I / II Trial of Irinotecan in Combination with Thalidomide for Treatment of Recurrent Glioblastoma Multiforme’ (FHCI protocol, undergoing IND/IRB review).

Principal Investigator ‘Phase II Treatment of Adults and Children with Progressive Recurrent Low Grade Gliomas with Temodar’ (Duke protocol, FH subsite)

Principal Investigator ‘Phase II Treatment of Adults with Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendrogloma with Temodar’ (Duke protocol, FH subsite) – closed.

Principal Investigator ‘Phase II Treatment of Adults with Recurrent Supratentorial Low Grade Glioma with Gliadel Wafers’ (Duke protocol, FH subsite)

Principal Investigator ‘Phase I Treatment of Adults with Primary Malignant Glioma with Irinotecan Plus BCNU’ (Duke protocol, FH subsite) – closed.

Principal Investigator ‘Phase I Treatment of Adults with Recurrent Supratentorial High Grade Glioma with Gliadel Wafers plus Irinotecan’ (Duke protocol, FH subsite)

Principal Investigator ‘Phase II Treatment of Adults with Brain Metastases with Temodar’ (Duke protocol, FH subsite)

Co-Principal Investigator ‘Treatment of Newly Diagnosed Glioblastoma Multiforme with Gliadel Wafers and Gamma-Knife’ (FH protocol) – closed.

Principal Investigator ‘Phase I Study of Intrathecal Spartaject (Busulfan) in Patients with Neoplastic Meningitis’ (Duke protocol, FH subsite)

Principal Investigator ‘Phase I Treatment of Adults with Primary Malignant Glioma with Topotecan Plus BCNU’ (Duke protocol, FH subsite) – closed.

Principal Investigator ‘Phase II Trial of Aricept in the Treatment of Adults with Memory, Cognitive, and Functional Sequelae Secondary to CNS Tumor’ (Duke protocol, FH subsite) – closed.

Principal Investigator ‘Phase II Treatement of Adults with Newly Diagnosed Glioblastoma Multiforme using Temodar’ (Duke protocol, FH subsite)

Co-Principal Investigator ‘Phase III Randomized Trial of Gadolinium Texaphyrin (PCI-0120) Injection as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases’ (MGH)

Co-Principal Investigator ‘A Dose Finding and Safety/Efficacy Trial of CPT-11 (Irinotecan) in Patients with Recurrent Malignant Gliomas’ (MGH)
 
Co-Principal Investigator ‘Trial of Intensive Chemotherapy and Autotransplantation for Patients with Newly Diagnosed Pure or Mixed Aggressive Oligodendrogliomas’ (MGH)

Co-Principal Investigator ‘Phase II Evaluation of ISIS 3521 Administered as a 21 Day Continuous Intravenous Infusion in Patients with Progressive or Recurrent High Grade Astrocytoma (NABTT 9706)’ (MGH)

Co-Principal Investigator ‘Phase II Randomized, Dose-Ranging Positive Controlled Trial of Human Corticotropin Releasing Factor in Symptomatic Brain Tumor Patients’ (MGH)

Subinvestigator ‘HN-66000 in the treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma’ (MUSC)


                                                                                                                            TO TOP

Sandra Tourt-Uhlig, Jennifer A. Quinn, Jeremy N. Rich, David A. Reardon, John H. Sampson, James M. Provenzale, Roger E. McLendon, Shari Edwards, Sridharan Gururangan, Mary L. Affronti, Waynette Buchanan, Susanne Jackson, Deborah Allen, Kara Penne, Christy Lentz, Darell D. Bigner, Michael Haglund, Allan H. Friedman, Nicholas Avgeropoulos, David Korones, Valerie Stafford-Fox, Sara Zaknoen, Henry S. Friedman, Duke University Medical Center, Durham, NC; Walt Disney Memorial Institute, Orlando, FL; The University of Rochester, Rochester, NY; Oncology Biotech, Chapel Hill, NC; Schering-Plough Research Institute, Kenilworth.  Phase II Trial of Temozolomide (Temodar®) in Patients with Progressive or Recurrent Low Grade Glioma.   

                                                                                                                              TO TOP

Shields DC, Avgeropoulos NG, Banik NL, Tyor WR. Acute multiple sclerosis characterized by extensive mononuclear phagocyte infiltration. Neurochemical Research. 2000;25:1517-1520.

Avgeropoulos N, Batchelor T (1999) New treatment strategies for malignant gliomas.  The Oncologist 4: 209-24.

Avgeropoulos N, Burris G, Ohlandt G, Wesselingh S, Markham R, Tyor WR (1998) Potential relationships between the presence of HIV, macrophages and astrogliosis in SCID mice with HIV encephalitis.  J NeuroAIDS 2:1-20.

Avgeropoulos N, Kelley B, Middaugh L, Arrigo S, Persidsky Y, Gendelman HE, Tyor WR (1998) SCID mice with HIV encephalitis develop behavioral abnormalities.  J Acq Immun Def Syn Hum Retrovirol 18: 13-20.

                                                                                                                                    TO TOP

                                                                                                                                        TO TOP

Home / General Neuro-Oncology Information / Physician Forms /  Patient Forms/ Protocols /

  United States Consultations/ International Consultations/ Patient Resources / 

Florida Hospital Cancer Institute / The Brain Tumor Center at Duke/ 

Links to Other Neuro-Oncology Sites /Contact Me